AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
AstraZeneca submitted a request for the FDA on Wednesday to approve a self-administered nasal flu vaccine for people ages two to 49 years old.